GLP-1 weight-loss drugs force employers to rethink health coverage
Rising use of GLP-1 weight‑loss drugs is driving up employer health costs, with about two‑thirds of firms still covering GLP-1s but roughly 10% planning to drop coverage next year. PepsiCo, Cigna and Starbucks have already narrowed or halted GLP-1 coverage, while Bank of America reports hundreds of millions spent on these drugs; some research suggests fewer sick days, complicating the cost‑benefit equation for employers.